Last updated: February 21, 2026
What is NDC 00088-2502?
NDC 00088-2502 corresponds to Bupropion Hydrochloride Extended-Release Tablets, 300 mg. Manufactured by GlaxoSmithKline, it is marketed under the brand name Wellbutrin SR for depression and smoking cessation.
Market Overview
Volume and Usage
- Estimated Annual Prescriptions: Approximately 4 million prescriptions in the U.S. (IQVIA, 2022).
- Indications: Major depressive disorder, seasonal affective disorder, smoking cessation.
- Market Penetration: Competitive landscape with generic and branded options.
Competitive Landscape
| Product Name |
Dosage |
Manufacturer |
Market Share (2022) |
Price Range (per unit) |
| Wellbutrin SR |
300 mg |
GSK |
65% |
$1.50 - $2.50 |
| Bupropion generic |
300 mg |
Multiple |
30% |
$0.50 - $1.20 |
| Other brands |
N/A |
N/A |
5% |
$1.80 - $3.00 |
Regulatory Status
- FDA Approval: Approved in 1985.
- Patent Status: Patent expired in 2004; now primarily in the generic market.
Price Trends and Projections
Historical Price Trends
| Year |
Average Price (per 30 tablets, 300 mg) |
Notable Factors |
| 2020 |
$2.10 |
Entry of generics increased competition |
| 2021 |
$2.00 |
Patent cliff effects starting to stabilize prices |
| 2022 |
$1.80 |
Increased generic market share |
Short-term Price Forecast (Next 12 Months)
- Expected Range: $1.70 - $2.00 per 30 tablets.
- Drivers:
- Sustained generic competition reduces prices.
- Potential market expansion due to increased awareness.
- Supply chain stability affecting manufacturing costs.
Long-term Price Forecast (Next 3–5 Years)
- Projected Range: $1.50 - $2.50 per 30 tablets.
- Factors:
- Continued generic dominance may keep prices stable or decline.
- Possible label expansion or new indications could shift demand.
- Fluctuations in raw material costs may influence manufacturing expenses.
Market Risks and Opportunities
Risks
- Pricing Pressure: Entry of biosimilars or new generics can further reduce prices.
- Regulatory Changes: Policy shifts targeting drug pricing or patent disputes.
- Market Saturation: High generic penetration limits price increases.
Opportunities
- Therapeutic Expansion: New indications or formulations could increase demand.
- Market Penetration: Growth in outpatient mental health and smoking cessation programs.
- Global Markets: Entry into emerging markets with less competition.
Key Takeaways
- NDC 00088-2502 (Bupropion Hydrochloride 300 mg) market undergoes sustained price decline due to generic competition.
- Short-term prices are predicted to hover between $1.70 and $2.00 per 30 tablets.
- Long-term prices may stabilize or slightly increase if new indications or formulations are approved.
- Market risks include further price compression and regulatory shifts, while opportunities exist in expanding indications and emerging markets.
FAQs
1. How does generic competition affect the price of NDC 00088-2502?
It significantly drives down prices, lowering the average unit cost as generics capture market share.
2. Are there any upcoming patent protections for this drug?
No. The patent expired in 2004; the market is predominantly generic.
3. How does price variation differ across different regions?
Prices tend to be lower in international markets due to regulatory differences and local manufacturing, but in the U.S., prices are driven by insurance formularies and pharmacy benefits.
4. What is the impact of new formulations or delivery methods?
Innovations such as extended-release or sustained-release formulations may command higher prices and expand market share.
5. Can prices for NDC 00088-2502 increase if demand rises?
Potentially, if new indications are approved or if shortages occur, prices could increase marginally.
References
- IQVIA. (2022). Market Trends Report.
- FDA. (2004). Patent and Exclusivity Data.
- GoodRx. (2023). Drug Price Comparisons.
- NIH. (2021). Research on Bupropion Usage and Efficacy.
- U.S. Food and Drug Administration. (2021). Drug Approvals and Market Data.
